MX2009006742A - Inhibidores acilaminopirazoles como fgfr. - Google Patents
Inhibidores acilaminopirazoles como fgfr.Info
- Publication number
- MX2009006742A MX2009006742A MX2009006742A MX2009006742A MX2009006742A MX 2009006742 A MX2009006742 A MX 2009006742A MX 2009006742 A MX2009006742 A MX 2009006742A MX 2009006742 A MX2009006742 A MX 2009006742A MX 2009006742 A MX2009006742 A MX 2009006742A
- Authority
- MX
- Mexico
- Prior art keywords
- novel compounds
- compound
- formula
- medicament
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Se proporciona un compuesto de Fórmula (I); o una sal farmacéuticamente aceptable del mismo. Así también proporciona un procedimiento para la preparación de un compuesto de Fórmula (I), y el uso de un compuesto de Fórmula (I) y como un medicamento y en el tratamiento del cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87119006P | 2006-12-21 | 2006-12-21 | |
US98554207P | 2007-11-05 | 2007-11-05 | |
PCT/GB2007/004917 WO2008075068A2 (en) | 2006-12-21 | 2007-12-20 | Acylaminopyrazoles as fgfr inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009006742A true MX2009006742A (es) | 2009-08-24 |
Family
ID=39536793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009006742A MX2009006742A (es) | 2006-12-21 | 2007-12-20 | Inhibidores acilaminopirazoles como fgfr. |
Country Status (29)
Country | Link |
---|---|
US (6) | US7737149B2 (es) |
EP (1) | EP2125748B1 (es) |
JP (1) | JP5000726B2 (es) |
KR (1) | KR101467593B1 (es) |
AR (1) | AR064454A1 (es) |
AT (1) | ATE510825T1 (es) |
AU (1) | AU2007336011B2 (es) |
BR (1) | BRPI0720551A2 (es) |
CA (1) | CA2672521C (es) |
CO (1) | CO6210721A2 (es) |
CY (1) | CY1111721T1 (es) |
DK (1) | DK2125748T3 (es) |
EC (1) | ECSP099436A (es) |
HK (1) | HK1139137A1 (es) |
HR (1) | HRP20110520T1 (es) |
IL (1) | IL199019A (es) |
MX (1) | MX2009006742A (es) |
MY (1) | MY146111A (es) |
NO (1) | NO342176B1 (es) |
NZ (1) | NZ577209A (es) |
PE (1) | PE20081532A1 (es) |
PL (1) | PL2125748T3 (es) |
PT (1) | PT2125748E (es) |
RU (1) | RU2458920C2 (es) |
SA (1) | SA07280734B1 (es) |
SI (1) | SI2125748T1 (es) |
TW (1) | TWI434846B (es) |
UY (1) | UY30819A1 (es) |
WO (1) | WO2008075068A2 (es) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
US8895745B2 (en) | 2006-12-22 | 2014-11-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
RS53144B (en) | 2007-08-22 | 2014-06-30 | Astrazeneca Ab. | DERIVATES CYCLOPROPIL AMIDA |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
DE102008028905A1 (de) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate |
AU2009261683A1 (en) * | 2008-06-19 | 2009-12-23 | Astrazeneca Ab | Pyrazole compounds 436 |
EP2361250B1 (en) | 2008-12-22 | 2013-08-07 | Merck Patent GmbH | Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
JO2860B1 (en) * | 2009-05-07 | 2015-03-15 | ايلي ليلي اند كومباني | Phenylendazolyl compounds |
US9012452B2 (en) | 2010-02-18 | 2015-04-21 | Astrazeneca Ab | Processes for making cyclopropyl amide derivatives and intermediates associated therewith |
US9045445B2 (en) | 2010-06-04 | 2015-06-02 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US9255072B2 (en) | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
EP2821402B1 (en) | 2012-02-28 | 2019-08-21 | Astellas Pharma Inc. | Nitrogen-containing aromatic heterocyclic compound |
KR20200046135A (ko) | 2012-03-08 | 2020-05-06 | 아스테라스 세이야쿠 가부시키가이샤 | 신규 fgfr3 융합체 |
WO2013161871A1 (ja) * | 2012-04-25 | 2013-10-31 | 興和株式会社 | Tlr阻害作用を有するチオフェン誘導体 |
HUE042374T2 (hu) | 2012-06-13 | 2019-06-28 | Incyte Holdings Corp | Szubsztituált triciklusos vegyületek mint FGFR inhibitorok |
WO2014002922A1 (ja) * | 2012-06-26 | 2014-01-03 | アステラス製薬株式会社 | 抗癌剤の併用による癌治療方法 |
US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US20140179712A1 (en) * | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
US9925240B2 (en) | 2013-03-06 | 2018-03-27 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
PL403149A1 (pl) * | 2013-03-14 | 2014-09-15 | Celon Pharma Spółka Akcyjna | Nowe związki pochodne pirazolilobenzo[d]imidazolu |
JP2016515508A (ja) | 2013-03-15 | 2016-05-30 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 融合タンパク質及びその方法 |
US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
KR102350704B1 (ko) | 2013-03-15 | 2022-01-13 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
AR096393A1 (es) * | 2013-05-23 | 2015-12-30 | Bayer Cropscience Ag | Compuestos heterocíclicos pesticidas |
US9931401B2 (en) | 2013-10-08 | 2018-04-03 | Daiichi Sankyo Company, Limited | Combination comprising anti-fibroblast growth factor receptor 2 (FGFR2) antibody and a tyrosine kinase inhibitor |
MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
CA2956270C (en) | 2014-08-18 | 2022-08-09 | Eisai R&D Management Co., Ltd. | Salt of monocyclic pyridine derivative and crystal thereof |
KR102022866B1 (ko) * | 2014-08-19 | 2019-09-19 | 상하이 하이헤 파마수티컬 컴퍼니 리미티드 | 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016105517A1 (en) | 2014-12-23 | 2016-06-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
JP7000321B2 (ja) | 2015-07-17 | 2022-02-10 | アンスティテュ・パストゥール | 衛星細胞の自己再生および/または分化の促進剤としての使用のための5-ヒドロキシトリプタミン1b受容体刺激剤 |
CN107406431B (zh) | 2015-08-20 | 2020-06-26 | 上海昂睿医药技术有限公司 | 吲哚类衍生物及其制备方法和其在医药上的用途 |
CN107459519A (zh) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
WO2018011382A1 (en) | 2016-07-15 | 2018-01-18 | Institut Pasteur | 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair |
CN107840842A (zh) | 2016-09-19 | 2018-03-27 | 北京天诚医药科技有限公司 | 炔代杂环化合物、其制备方法及其在医药学上的应用 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CA3091153A1 (en) | 2018-03-28 | 2019-10-03 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
AU2019262579A1 (en) | 2018-05-04 | 2020-12-24 | Incyte Corporation | Salts of an FGFR inhibitor |
AU2019262195A1 (en) | 2018-05-04 | 2020-12-24 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
WO2020243459A1 (en) * | 2019-05-31 | 2020-12-03 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
BR112022007163A2 (pt) | 2019-10-14 | 2022-08-23 | Incyte Corp | Heterociclos bicíclicos como inibidores de fgfr |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TW202237595A (zh) * | 2020-12-02 | 2022-10-01 | 美商愛德亞生物科學公司 | 作為DNA聚合酶θ抑制劑之經取代噻二唑基衍生物 |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
WO2023060573A1 (en) * | 2021-10-15 | 2023-04-20 | Beijing Danatlas Pharmaceutical Co., Ltd. | Novel thiadiazolyl derivatives of dna polymerase theta inhibitors |
WO2023180388A1 (en) | 2022-03-24 | 2023-09-28 | Glaxosmithkline Intellectual Property Development Limited | 2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs |
WO2024031226A1 (zh) * | 2022-08-08 | 2024-02-15 | 无锡和誉生物医药科技有限公司 | Fgfr抑制剂的药物组合物、多晶型物及其在药学上的应用 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB843940A (en) | 1955-09-27 | 1960-08-10 | Kodak Ltd | Method of processing photographic silver halide emulsions containing colour couplers |
BE667399A (es) | 1964-07-30 | 1965-11-16 | ||
JPS57150846A (en) * | 1981-03-13 | 1982-09-17 | Konishiroku Photo Ind Co Ltd | Photographic element |
JPS63133152A (ja) | 1986-11-26 | 1988-06-04 | Konica Corp | 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料 |
JPH0467645A (ja) | 1990-07-09 | 1992-03-03 | Nec Kyushu Ltd | バーンイン装置 |
JP2890065B2 (ja) | 1990-11-10 | 1999-05-10 | コニカ株式会社 | ハロゲン化銀写真感光材料 |
JPH04184437A (ja) | 1990-11-20 | 1992-07-01 | Fuji Photo Film Co Ltd | カラー画像形成方法及びハロゲン化銀カラー写真感光材料 |
JPH04292322A (ja) | 1991-03-19 | 1992-10-16 | Fujitsu Ltd | ラック給排装置 |
JPH0511414A (ja) * | 1991-07-02 | 1993-01-22 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
PL170837B1 (pl) * | 1991-10-18 | 1997-01-31 | Monsanto Co | S rod ek g r zybobó j c zy PL PL PL PL PL PL |
BR9305466A (pt) | 1992-03-26 | 1994-12-20 | Dowelanco | Nitroanilinas n-heterocíclicas usadas como fungicidas |
HRP921338B1 (en) * | 1992-10-02 | 2002-04-30 | Monsanto Co | Fungicides for the control of take-all disease of plants |
TW240217B (es) | 1992-12-30 | 1995-02-11 | Glaxo Group Ltd | |
JP3156026B2 (ja) | 1993-12-27 | 2001-04-16 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
ATE262902T1 (de) | 1994-11-10 | 2004-04-15 | Millennium Pharm Inc | Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose |
ATE443698T1 (de) | 1996-12-23 | 2009-10-15 | Bristol Myers Squibb Pharma Co | Stickstoffhaltige heterocyclen als faktor xa- hemmer |
CA2302438A1 (en) | 1997-05-19 | 1998-11-26 | Sugen, Inc. | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders |
WO1998052941A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
US6271237B1 (en) * | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
JP4395823B2 (ja) * | 1997-12-22 | 2010-01-13 | バイエル コーポレイション | アリール及びヘテロアリール置換複素環式尿素を用いたrafキナーゼの阻害 |
JP3310226B2 (ja) | 1998-10-16 | 2002-08-05 | 松下電器産業株式会社 | 音声合成方法および装置 |
GB9823103D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
CN1230421C (zh) * | 1999-02-10 | 2005-12-07 | 三菱制药株式会社 | 酰胺化合物及其药物用途 |
WO2000049001A2 (en) | 1999-02-16 | 2000-08-24 | E.I. Du Pont De Nemours And Company | Phenoxy-, phenylthio-, phenylamino-, benzyloxy-, benzylthio- or benzylaminopyrimidine insectidices and acaricides |
CN1222520C (zh) | 1999-08-12 | 2005-10-12 | 沃泰克斯药物股份有限公司 | c-JUN N-末端激酶(JNK)和其它蛋白激酶的抑制剂 |
EP1202733B1 (en) | 1999-08-12 | 2005-10-05 | Pharmacia Italia S.p.A. | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
ATE350044T1 (de) * | 1999-09-24 | 2007-01-15 | Smithkline Beecham Corp | Thrombopoietinmimetika |
US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
IL154016A0 (en) * | 2000-08-31 | 2003-07-31 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
WO2002024656A1 (fr) * | 2000-09-22 | 2002-03-28 | Nihon Nohyaku Co., Ltd. | Derives de n-(4-pyrazolyl amide, produits chimiques pour utilisation agricole et horticole et applications desdits derives |
ATE548031T1 (de) * | 2000-12-18 | 2012-03-15 | Inst Med Molecular Design Inc | Inhibitoren gegen die produktion und freisetzung entzündungfördernder zytokine |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
WO2002088090A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitors |
AU2003242131A1 (en) | 2002-06-05 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc. | Immunity-related protein kinase inhibitors |
WO2003103648A1 (ja) | 2002-06-05 | 2003-12-18 | 株式会社医薬分子設計研究所 | 糖尿病治療薬 |
AU2003242103A1 (en) | 2002-06-06 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc | Antiallergic agents |
ES2246603B1 (es) | 2002-07-03 | 2007-06-16 | Consejo Sup. De Investig. Cientificas | Procedimiento para la preparacion de esteres de hidroxitirosol, esteres obtenidos y utilizacion. |
EP1541563A4 (en) | 2002-07-10 | 2007-11-07 | Ono Pharmaceutical Co | ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE |
JP2005537297A (ja) * | 2002-08-01 | 2005-12-08 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | アルファ−7nachr活性を有する1h−ピラゾールおよび1h−ピロール−アザビシクロ化合物 |
JP4171881B2 (ja) | 2002-08-09 | 2008-10-29 | 株式会社大塚製薬工場 | Acat−1阻害剤 |
ATE479667T1 (de) | 2003-02-06 | 2010-09-15 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis |
JP2004292322A (ja) | 2003-03-25 | 2004-10-21 | Fuji Photo Film Co Ltd | 水溶性アミド連結体の製造方法 |
DK1618092T3 (da) | 2003-05-01 | 2011-01-31 | Bristol Myers Squibb Co | Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere |
US20040220170A1 (en) * | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
US7115359B2 (en) * | 2003-07-25 | 2006-10-03 | Konica Minolta Medical & Graphic, Inc. | Photothermographic material |
MXPA06002017A (es) | 2003-08-21 | 2006-05-31 | Osi Pharm Inc | Pirazolil-amidil-bencimidazolilo n-sustituidos, ibnhibidores de c-kit. |
US7432271B2 (en) * | 2003-09-02 | 2008-10-07 | Bristol-Myers Squibb Company | Pyrazolyl inhibitors of 15-lipoxygenase |
US20050148605A1 (en) | 2003-11-13 | 2005-07-07 | Ambit Biosciences Corporation | Amide derivatives as ABL modulators |
US7671072B2 (en) | 2003-11-26 | 2010-03-02 | Pfizer Inc. | Aminopyrazole derivatives as GSK-3 inhibitors |
US7652146B2 (en) * | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
US7253204B2 (en) * | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2005105780A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
RU2008107868A (ru) | 2005-08-02 | 2009-09-10 | Айрм Ллк (Bm) | Соединения и композиции в качестве ингибиторов протеинкиназ |
US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
-
2007
- 2007-12-18 US US11/958,720 patent/US7737149B2/en active Active
- 2007-12-19 AR ARP070105731A patent/AR064454A1/es not_active Application Discontinuation
- 2007-12-20 WO PCT/GB2007/004917 patent/WO2008075068A2/en active Application Filing
- 2007-12-20 DK DK07848646.1T patent/DK2125748T3/da active
- 2007-12-20 RU RU2009127644/04A patent/RU2458920C2/ru active
- 2007-12-20 JP JP2009542220A patent/JP5000726B2/ja not_active Expired - Fee Related
- 2007-12-20 TW TW096149024A patent/TWI434846B/zh active
- 2007-12-20 NZ NZ577209A patent/NZ577209A/en not_active IP Right Cessation
- 2007-12-20 UY UY30819A patent/UY30819A1/es not_active Application Discontinuation
- 2007-12-20 EP EP07848646A patent/EP2125748B1/en active Active
- 2007-12-20 SI SI200730655T patent/SI2125748T1/sl unknown
- 2007-12-20 PL PL07848646T patent/PL2125748T3/pl unknown
- 2007-12-20 PT PT07848646T patent/PT2125748E/pt unknown
- 2007-12-20 AT AT07848646T patent/ATE510825T1/de active
- 2007-12-20 MY MYPI20092608A patent/MY146111A/en unknown
- 2007-12-20 CA CA2672521A patent/CA2672521C/en active Active
- 2007-12-20 MX MX2009006742A patent/MX2009006742A/es active IP Right Grant
- 2007-12-20 KR KR1020097014263A patent/KR101467593B1/ko active IP Right Grant
- 2007-12-20 BR BRPI0720551-1A patent/BRPI0720551A2/pt not_active Application Discontinuation
- 2007-12-20 AU AU2007336011A patent/AU2007336011B2/en active Active
- 2007-12-29 SA SA07280734A patent/SA07280734B1/ar unknown
-
2008
- 2008-01-02 PE PE2008000012A patent/PE20081532A1/es active IP Right Grant
-
2009
- 2009-05-26 NO NO20092033A patent/NO342176B1/no not_active IP Right Cessation
- 2009-05-27 IL IL199019A patent/IL199019A/en active IP Right Grant
- 2009-06-16 EC EC2009009436A patent/ECSP099436A/es unknown
- 2009-06-17 CO CO09062879A patent/CO6210721A2/es active IP Right Grant
-
2010
- 2010-04-30 US US12/771,661 patent/US8129391B2/en active Active
- 2010-05-20 HK HK10104975.9A patent/HK1139137A1/xx unknown
-
2011
- 2011-07-11 HR HR20110520T patent/HRP20110520T1/hr unknown
- 2011-07-20 CY CY20111100721T patent/CY1111721T1/el unknown
-
2012
- 2012-01-26 US US13/359,008 patent/US8604022B2/en active Active
-
2013
- 2013-11-13 US US14/078,918 patent/US20140066455A1/en not_active Abandoned
-
2015
- 2015-06-26 US US14/751,381 patent/US9688640B2/en active Active
-
2017
- 2017-05-26 US US15/606,141 patent/US10301267B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006742A (es) | Inhibidores acilaminopirazoles como fgfr. | |
MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
TW200738725A (en) | Unsaturated mTOR inhibitors | |
TW200833663A (en) | Therapeutic agents | |
SG148177A1 (en) | Novel cis-imidazolines | |
GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
HK1121440A1 (en) | Biphenyl derivatives and their use in treating hepatitis c | |
DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
EP2400847A4 (en) | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | |
HK1091121A1 (en) | Substituted 2-aminotetralins for the treatment of depressions | |
EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
MX2009004096A (es) | Metabolitos de talarozol. | |
MX2007013624A (es) | Inhibidores de proteina cinasa. | |
HK1094425A1 (en) | Substituted 2-aminotetralines for the preventive treatment of parkinson's disease | |
UA96969C2 (en) | Acylaminopyrazoles as fgfr inhibitors | |
TW200740776A (en) | N-phenylbenzotriazolyl c-kit inhibitors | |
NZ593440A (en) | Aminopyrazole compounds useful for inhibiting chk1 | |
UA85707C2 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
MX2008016134A (es) | Derivados de fenol para el tratamiento de enfermedades respiratorias. | |
TW200639156A (en) | New compounds | |
EP2639229A3 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
WO2008020027A3 (en) | 2,5-dihydroxybenzene compounds for the treatment of skin cancer | |
UA96304C2 (en) | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | |
MX2009003081A (es) | Derivados de pirrola utiles para el tratamiento de enfermedades mediadas por citoquinas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |